Single Postoperative Instillation of Gemcitabine in Patients with Non-muscle-invasive Transitional Cell Carcinoma of the Bladder: A Randomised, Double-blind, Placebo-controlled Phase III Multicentre Study

医学 吉西他滨 泌尿科 移行细胞癌 内科学 安慰剂 膀胱癌 外科 化疗 癌症 病理 替代医学
作者
Andreas Böhle,H. Leyh,Christian Frei,Michael Kühn,Reinhold Tschada,Tobias Pottek,Walter Wagner,Helmut H. Knispel,Wolfgang von Pokrzywnitzki,Ferruh Zorlu,Karin Helsberg,Birgit Lübben,Victoria Soldatenkova,C. Stoffregen,Hartwig Büttner
出处
期刊:European Urology [Elsevier BV]
卷期号:56 (3): 495-503 被引量:107
标识
DOI:10.1016/j.eururo.2009.06.010
摘要

Recurrence prophylaxis with intravesical gemcitabine (GEM) was effective and safe in patients with non-muscle-invasive bladder cancer (NMIBC); efficacy as single-shot instillation remains to be proved. To compare the efficacy of a single GEM instillation versus placebo (PBO) immediately after transurethral resection (TUR) of tumour in patients with histologically confirmed NMIBC (pTa/pT1,G1–3). This was a double-blind, randomised, PBO-controlled study in patients with clinical evidence of primary or recurrent NMIBC (Ta/T1,G1–3). Of 355 patients randomised at 24 urologic centres, 328 underwent TUR and received instillation (92.4%; GEM/PBO: 166/162). In case of nonmalignancy, carcinoma in situ (CIS), ≥pT2 disease, or intraoperative complications, patients were discontinued. We used a single, postoperative 30–40-min instillation of GEM (2000 mg/100 ml of saline) or PBO (100 ml of saline) followed by continuous bladder irrigation for ≥20 h. A second TUR (no instillation) and adjuvant bacillus Calmette-Guérin (BCG) instillations were allowed. Primary outcome was recurrence-free survival (RFS). Secondary outcomes included type of recurrence and adverse events. To detect a difference in RFS, 191 recurrences were required (80% power, log-rank-test, α = 0.050). Two hundred forty-eight patients (69.9%, GEM, PBO: 124, 124) had histologically confirmed pTa/pT1 G1–3 Gx tumour and were eligible for efficacy (GEM: 76.6% male; median age: 65 yr; PBO: 83.1% male; median age: 67 yr). Treatment groups were balanced (pTa: 75.0%, 71.0%; G1–G2: 85.5%, 87.9%; recurrent tumour: 24.2%, 21.0%; BCG: 10.5%, 16.9%). After a median follow-up of 24 mo, there were only 94 recurrences and 11 deaths. The study was terminated early based on predefined decision criteria. RFS was high in both groups (12-mo RFS [95% confidence interval (CI)]: GEM: 77.7% [68.8–84.3]; PBO: 75.3% [66.3–82.3]). There was no significant group difference (hazard ratio [HR]: 0.946 [0.64–1.39], log-rank test, p = 0.777). In this study of NMIBC, the immediate single instillation of GEM 2000 mg/100 ml of saline after TUR was not superior to PBO in terms of RFS. Rigid continuous irrigation and improved TUR/cystoscopy techniques may have contributed to the high RFS in both groups.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
bkagyin应助zz采纳,获得10
1秒前
77发布了新的文献求助10
1秒前
NIUBEN发布了新的文献求助10
1秒前
tingting发布了新的文献求助10
1秒前
2秒前
2秒前
美好丹妗完成签到,获得积分10
2秒前
狄谷南发布了新的文献求助10
2秒前
zzz发布了新的文献求助10
3秒前
3秒前
xia发布了新的文献求助10
3秒前
znn发布了新的文献求助10
3秒前
桐桐应助昵昵昵昵呀采纳,获得10
4秒前
log发布了新的文献求助10
4秒前
TGU2331161488发布了新的文献求助10
4秒前
4秒前
明理的霸完成签到,获得积分10
5秒前
6秒前
6秒前
yue957完成签到,获得积分10
6秒前
今后应助csu_zs采纳,获得10
6秒前
大个应助帅气的可乐采纳,获得10
8秒前
大宝慧发布了新的文献求助10
8秒前
8秒前
晴天完成签到,获得积分10
9秒前
FireNow完成签到,获得积分10
9秒前
10秒前
温热如河应助zhangyu采纳,获得10
10秒前
xy完成签到,获得积分10
10秒前
Lucas应助付品聪采纳,获得10
10秒前
yue957发布了新的文献求助10
10秒前
希望天下0贩的0应助77采纳,获得10
11秒前
zzr真真97发布了新的文献求助10
11秒前
11秒前
狄谷南完成签到,获得积分10
11秒前
脑洞疼应助潘2333采纳,获得10
11秒前
SciGPT应助Chong采纳,获得10
12秒前
12秒前
13秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974712
求助须知:如何正确求助?哪些是违规求助? 3519159
关于积分的说明 11197254
捐赠科研通 3255257
什么是DOI,文献DOI怎么找? 1797724
邀请新用户注册赠送积分活动 877130
科研通“疑难数据库(出版商)”最低求助积分说明 806132